Metacrine

OverviewSuggest Edit

Metacrine is a biotech company developing innovative therapeutics for metabolic diseases. The company is led by an experienced management team and backed by leading institutional investors. Founded in 2015, Metacrine’s initial technology was licensed from the laboratory of Dr. Ronald Evans, a world leader in nuclear hormone receptors and Howard Hughes Medical Institute Investigator at the Salk Institute. The current focus of the company is to develop novel therapeutics for significant metabolic diseases such as type 2 diabetes and non-alcoholic steatohepatitis (NASH). There are over 30 million type 2 diabetics in the United States and despite numerous available drug classes, close to 50% of patients are unable to achieve target HbA1c levels and glucose control. Similarly, non-alcoholic steatohepatitis (NASH) is reaching epidemic proportions in the US and worldwide, with nearly 20% of Americans having some stage of fatty liver disease. Currently, there is no approved therapy for NASH. Metacrine will leverage two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders.
TypePrivate
Founded2015
HQSan Diego, US
Websitemetacrine.com

Latest Updates

Employees (est.) (Oct 2020)32
Cybersecurity ratingBMore

Key People/Management at Metacrine

Preston Klassen

Preston Klassen

President and Chief Executive Officer
Trisha Millican

Trisha Millican

Chief Financial Officer
Hubert Chen

Hubert Chen

Chief Medical Officer
Nicholas Smith

Nicholas Smith

Senior Vice President, Chemistry
Catherine Lee

Catherine Lee

Senior Vice President, General Counsel
Eric Bischoff

Eric Bischoff

Vice President, Development and Operations
Show more

Metacrine Office Locations

Metacrine has an office in San Diego
San Diego, US (HQ)
3985 Sorrento Valley Blvd Suite C
Show all (1)

Metacrine Financials and Metrics

Summary Metrics

Founding Date

2015

Metacrine total Funding

$123 m

Metacrine latest funding size

$65 m

Time since last funding

2 years ago

Metacrine investors

Metacrine's latest funding round in June 2018 was reported to be $65 m. In total, Metacrine has raised $123 m
Show all financial metrics

Metacrine Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Metacrine Online and Social Media Presence

Embed Graph

Metacrine News and Updates

Metacrine prices IPO, to raise $85 million

Metacrine Inc.'s initial public offering priced overnight as the biopharmaceutical company, focused on developing treatments for liver and gastrointestinal diseases, raised $85.0 million. The San Diego-based company sold 6.54 million shares at $13 a share, which was in the middle of the expected ra…

Metacrine Announces Pricing of Initial Public Offering

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced the pricing of its initial public offering …

NASH biotech Metacrine files for a $100 million IPO

Metacrine, a Phase 1 biotech developing FXR agonist therapies for NASH, filed on Monday with the SEC to raise up to $100 million in an initial public offering.

Metacrine Demonstrates Best-in-Class FXR Drug Program with Positive Clinical Results in NASH Patients

SAN DIEGO, Jan. 22, 2020 /PRNewswire/ -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, announced topline results from a 12-week, randomized, placebo-controlled...

Metacrine Blogs

Executive Director, Clinical Development (EDCD)

Job Description Metacrine is a dynamic, clinical-stage biotech company headquartered in San Diego, CA. The company is focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. We are looking for an Executive Director of Clinical Development …

Metacrine to Present at Jefferies 2019 London Healthcare Conference

SAN DIEGO, November 18, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Ken Song, M.D., President and CEO, will present at the Jefferies 2019 Londo…

Metacrine to Present at H.C. Wainwright 2019 NASH Investor Conference

SAN DIEGO, October 15, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced that Hubert Chen, M.D., Chief Medical Officer, will present at the H.C. Wainwrigh…

Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures

SAN DIEGO, September 18, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, today announced it has entered into a loan and security agreement for up to $50 million with K2…

Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist

Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist SAN DIEGO, July 9, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat…

Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019

Promising signs of clinical efficacy without increase in LDL cholesterol SAN DIEGO, July 2, 2019 – Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present initial clinica…
Show more

Metacrine Frequently Asked Questions

  • When was Metacrine founded?

    Metacrine was founded in 2015.

  • Who are Metacrine key executives?

    Metacrine's key executives are Preston Klassen, Trisha Millican and Hubert Chen.

  • How many employees does Metacrine have?

    Metacrine has 32 employees.

  • Who are Metacrine competitors?

    Competitors of Metacrine include Cell Genesys, Vitrolife and PamBio.

  • Where is Metacrine headquarters?

    Metacrine headquarters is located at 3985 Sorrento Valley Blvd Suite C, San Diego.

  • Where are Metacrine offices?

    Metacrine has an office in San Diego.

  • How many offices does Metacrine have?

    Metacrine has 1 office.